CL
Therapeutic Areas
FibroBiologics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CybroCell™ | Degenerative Disc Disease (DDD) | Clinical |
| CYMS101 | Multiple Sclerosis | Pre-clinical / Limited Clinical |
| CYWC628 | Wound Healing (Diabetic Foot Ulcers, Venous Leg Ulcers, burns) | Pre-clinical |
| CYPS317 | Psoriasis | Discovery |
| CYTER915 | Cancer Immunotherapy | Discovery |
| TBC190 | Thymic Involution Reversal | Discovery |
| CYAPO913 | Diabetes | Discovery |
| Unnamed Spleen Program | Splenic Involution Reversal | Discovery |
Leadership Team at FibroBiologics
PO
Pete O'Heeron
Chairman/Founder/CEO
JD
Jason D. Davis
Chief Financial Officer
HK
Hamid Khoja, Ph.D.
Chief Scientific Officer
RG
Ruben Garcia, JD
General Counsel
RE
Robert E. Hoffman
Board of Directors
SC
Stacy Coen, MBA
Board of Directors
ML
Matt Link
Board of Directors
VN
Victoria Niklas, M.D.
Board of Directors
RC
Richard C. Cilento, Jr.
Board of Directors
ST
S. Thomas Carmichael, M.D., Ph.D.
Scientific Advisory Board